Continuing clozapine treatment despite neutropenia

  • Esposito D
  • Rouillon F
  • Limosin F
  • 29


    Mendeley users who have this article in their library.
  • 29


    Citations of this article.


Approximately 1-2% of patients treated with the atypical antipsychotic clozapine develop severe neutropenia and agranulocytosis. The usual recommendation is to discontinue treatment with the drug when the peripheral neutrophil count drops below 1,500/mm3.

Author-supplied keywords

  • Agranulocytosis
  • Clozapine
  • Granulopoiesis-stimulating factors
  • Lithium
  • Neutropenia

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • David Esposito

  • Frédéric Rouillon

  • Frédéric Limosin

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free